Candel Therapeutics, Inc. CADL
Regular-session close
After hours · Nov 19, 7:52 PM ET
- YTD
- -9.20%
- 1 year
- +16.06%
5D -0.67 (-11.49%)
- Market cap
- 402.43M
- EPS (ttm)
- -1.53
- Shares out
- 76.52M
- Forward P/E
- -21.12
- YTD return
- -9.20%
- 1-year return
- +16.06%
- 50-day average
- 10.75
- 200-day average
- 7.27
- Volume
- 1.19M
- Avg volume
- 1.26M
- Open
- 5.38
- Previous close
- 5.32
- Day's range
- 5.07 – 5.45
- 52-week range
- 4.35 – 14.00
- Beta
- -0.50
- Price target
- 21.00 (+309.4%)
Key statistics
- Enterprise value
- 831.22M
- Price / book
- 7.97
- Free cash flow
- -35.75M
- Total cash
- 201.56M
- Total debt
- 49.52M
- Return on equity
- -81.84%
- Short % of float
- 20.94%
Fundamental scorecard
4 of 25 checks passed on CADL’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.30 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.23793 | -0.52 | -0.28 | -118.55% |
| May 14, 2026 | Mar 31, 2026 | -0.22 | -0.14 | +0.08 | +36.36% |
| Mar 12, 2026 | Dec 31, 2025 | -0.24 | -0.54 | -0.30 | -125.00% |
| Nov 13, 2025 | Sep 30, 2025 | -0.17 | -0.21 | -0.04 | -23.53% |
| Aug 14, 2025 | Jun 30, 2025 | -0.17 | -0.09 | +0.08 | +47.06% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | B of A Securities | main | Neutral | Neutral |
| Aug 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 13, 2026 | Stifel | init | — | Buy |
| Apr 20, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Mar 18, 2026 | Citigroup | main | Buy | Buy |
| Mar 13, 2026 | Citigroup | main | Buy | Buy |
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- candeltx.com
News
Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens Berman
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Candel Therapeutics (CADL)
CADL INVESTORS: Securities Fraud Investigation by Block & Leviton Could Allow Candel Therapeutics Investors to Recover Losses
CADL Investors Have Opportunity to Join Candel Therapeutics, Inc. Fraud Investigation with SBS Law
Candel Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Candel Therapeutics (CADL)
Candel Therapeutics: Upgrade Despite The Recent Prostate Filing Delay
Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower – HBSS Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $20
Candel Therapeutics, Inc. $CADL Shares Newly Purchased by ACT Capital Partners L.P. HC Wainwright & Co. Maintains Buy on Candel Therapeutics, Lowers Price Target to $18
Your note
Sign in to keep a note on CADL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGUILAR-CORDOVA ESTUARDO | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 14, 2024 | 6,053,780 |
| BARONE FRANCESCA | Officer | Sale | Jun 28, 2026 | 77,362 |
| MANNING PAUL B. | Director | Purchase | Feb 22, 2026 | 0 |
| MARTELL CHRISTOPHER | Director | Stock Award(Grant) | Jun 24, 2025 | 0 |
| NABEL GARY J. | Director | Stock Award(Grant) | Jun 24, 2025 | 5,353 |
| NICHOLS WILLIAMS GARRETT | Officer | Sale | Jul 27, 2025 | 52,493 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.36% | 10,990,535 | 145.08M | Jun 29, 2026 |
| RTW Investments LP | 8.39% | 6,422,018 | 84.77M | Jun 29, 2026 |
| Blackrock Inc. | 6.49% | 4,969,040 | 65.59M | Jun 29, 2026 |
| State Street Corporation | 4.64% | 3,549,823 | 46.86M | Jun 29, 2026 |
| Acorn Capital Advisors, LLC | 4.57% | 3,497,948 | 46.17M | Jun 29, 2026 |
| Portolan Capital Management, LLC | 4.56% | 3,490,398 | 46.07M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 6.36% | 4,864,753 | 64.21M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.76% | 2,108,466 | 27.83M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.65% | 2,024,039 | 26.72M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.57% | 1,968,034 | 25.98M | Mar 30, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 2.50% | 1,911,115 | 25.23M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 1,650,828 | 21.79M | Jun 29, 2026 |
